The hedge fund business continues to hemorrhage assets – over $16 billion in the last six months. “As a group, hedge funds have suffered horrid performance for more than two years,” said Bryan Anderson, Vice-President & Market Strategist for Beck Capital Management. “Valeant Pharmaceuticals was a favorite of hedge funds beginning early in 2013. Last year it imploded and caused significant losses in several hedge funds, including Pershing Square, managed by Bill Ackman (pictured above). At our firm, we view hedge funds as high-risk investment vehicles, not worth their high fees given their very mediocre performance.” To view a recent story in Bloomberg covering the large redemptions in hedge funds, click here.